Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD/MAD study of KHK6640 in Alzheimer's disease
NL-OMON44211Phase 1Active, not recruiting
- Sponsor
- Kyowa Kirin
- Start
- Oct 2014
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of KHK6640 in Alzheimer's disease (AD) (6 arms), sponsored by Kyowa Kirin. Primary endpoint: Safety and tolerability. Started Oct 2014; status: active, not recruiting.
02
Drugs
KHK6640
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NL-OMON44211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44211.